IMB Dx, Inc. products

AlphaLiquid®10 is designed to detect mutations in 10 colorectal cancer-related genes. It can be used in companion diagnostics to provide information on whether recurrence or metastasis might be occurring after treatment.

AlphaLiquid®Screening is able to detect cancer faster than imaging tests such as CT or MRI scan. It is designed to screen and detect cancer early by identifying where the cancer first originated in the body. This allows the doctor to begin treatment at an earlier stage which increases the patient’s chances of survival.

AlphaLiquid®1000 is a pan-cancer assay for almost all known types of solid cancer patients, designed to examine more than a 1000 genes related to different cancers at once. It, too, can be used in companion diagnostics to detect and monitor signs of relapse and/or metastasis after beginning anticancer drug therapy.

AlphaLiquid® Screening is a blood-based test for early detection of multiple cancers. With 10mL of blood, the test analyzes genetic and epigenetic features in cfDNA to screen for signals of cancer as well as predict the tissue of origin.

AlphaLiquid® Detect is an industry-first tumor-informed, hybrid-capture NGS-based liquid biopsy test designed for MRD detection and recurrence monitoring in stage I-III solid tumor patients. The assay incorporates a personalized panel of up to 1,000 targets, including both tumor-informed patient-specific markers as well as additional therapeutic targets. By delivering exceptional detection levels (<0.005% LOD), AlphaLiquid® Detect provides clinically actionable information for relapse monitoring and adjuvant therapy guidance with a significant lead time over conventional imaging diagnostics.